Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Identification of Human Tumor Antigens Recognized by T-Cells and Their Use for Immunotherapy

  • 46 Accesses

  • 1 Citations

Abstract

Identification of human tumor antigens led to development of new immunotherapies for patients with cancer. Identification of T-cell epitopes allowed us to monitor antitumor T-cell responses quantitatively and qualitatively during immunotherapy as well as to develop more efficient immunotherapies with sufficient amounts of antigens in more immunogenic forms. Various immunotherapies, passive immunotherapies, including adoptive transfer of tumor reactive T-cells or allo-geneic antigen-specific donor T-cells, and active immunization with identified tumor antigens or dendritic cells pulsed with tumor antigens are being evaluated in clinical trials. Although tumor regression has been observed in some patients, further improvement is required.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Wang R, Wang X, Johnston S, Zeng G, Robbins P, Rosenberg S. Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens.Cancer Res. 1998;58: 3519–3525.

  2. 2.

    Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen.Science. 1999;284:1351–1354.

  3. 3.

    denHaan JMM, Meadows LM, Wang W, et al. The minor histo- compatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism.Science. 1998;279:1054–1057.

  4. 4.

    Touloukian CE, Leitner WW, Topalian SL, et al. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.J Immunol. 2000;164:3535–3542.

  5. 5.

    Jager E, Nagata Y, Gnjatic S, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.Proc Natl Acad Sci USA. 2000;97:4760–4765.

  6. 6.

    Kawakami Y, Suzuki Y, Shofuda T, et al. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity.Pigment Cell Res. 2000;13:163–169.

  7. 7.

    Brinkmann U, Vasmatzis G, Lee B, Pastan I. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database.Cancer Res. 1999;59:1445–1448.

  8. 8.

    Romero, Cerottini JC, Waanders GA. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunother- apy.Mol Med Today. 1998;4:305–312.

  9. 9.

    Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.Nat Med. 1999;5:677–685.

  10. 10.

    Rosenberg S, Yang J, Schwartzentruber D, et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.J Immunol. 1999;163:1690–1695.

  11. 11.

    Panelli MC, Riker A, Kammula U, et al. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.J Immunol. 2000;164:495–504.

  12. 12.

    Parkhurst MR, Salgaller M, Southwood S, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 binding residues.J Immunol. 1996;157:2539–2548.

  13. 13.

    Tsuboi A, Oka Y, Udaka K, et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.Cancer Immunol Immunother. 2002;51:614–620.

  14. 14.

    Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.Proc Natl Acad Sci USA. 2001;98:8809–8814.

  15. 15.

    Robbins PF, El-Gamil M, Li YF, et al. A mutated ß-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.J Exp Med. 1996;183:1185–1192.

  16. 16.

    Rubinfeld B, Robbins P, El-Gamil M, Albert I, Prfiri E, PolakisP. Stabilization of beta-catenin by genetic defects in melanoma cell lines.Science. 1997;275:1790–1792.

  17. 17.

    Wolfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.Science. 1995;269:1281–1284.

  18. 18.

    Baurain JF, Colau D, vanBaren N, et al. High frequency of auto-logous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene.J Immunol. 2000;164: 6057–6066.

  19. 19.

    Yotnda P, Firat H, Garcia-Pons F, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.J Clin Invest. 1998;101:2290–2296.

  20. 20.

    Yotnda P, Garcia F, Peuchmaur M, et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia.J Clin Invest. 1998;102:455–462.

  21. 21.

    Yun C, Senju S, Fujita H, et al. Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein.Tissue Antigens. 1999;54:153–161.

  22. 22.

    Yasukawa M, Ohminami H, Kaneko S, et al. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.Blood. 1998;92:3355–3361.

  23. 23.

    D’Souza S, Rimoldi D, Lienard D, Lejeune F, Cerottini J, Romero P. Circulating melan-A/MART-1 specific cytolytic T lymphocyte precursors in HLA-A2(+)melanoma patients have a memory phenotype.Int J Cancer. 1998;78:699–706.

  24. 24.

    Dunbar PR, Smith CL, Chao D, et al. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response.J Immunol. 2000;165:6644–6652.

  25. 25.

    Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 associated with in vivo tumor regression.J Immunol. 1995;154:3961–3968.

  26. 26.

    Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.Int J Cancer. 1996;66:470–476.

  27. 27.

    Rosenberg S, Yang J, Schwartzentruber D, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.Nat Med. 1998;4: 321–327.

  28. 28.

    Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with anti-tumor lymphocytes.Science. 2002;298:850–854.

  29. 29.

    Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo.J Exp Med. 2000;192:1637–1644.

  30. 30.

    Lally KM, Mocellin S, Ohnmacht GA, et al. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading.IntJ Cancer. 2001;93:841–847.

  31. 31.

    Murphy GP, Tjoa BA, Simmons SJ, et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment.Prostate. 1999;39:54–59.

  32. 32.

    Murphy GP,Tjoa BA, Simmons SJ, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease.Prostate. 1999;38: 73–78.

  33. 33.

    Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.Blood. 1997;90:2529–2534.

  34. 34.

    Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.Nat Med. 2000;6:1018–1023.

  35. 35.

    Cormier J, Hijazi Y, Abati A, et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.Int J Cancer. 1998;75:517–524.

  36. 36.

    Marchand M, Baren N, Weynants P,et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by MAGE-3 and presented by HLA-A1.IntJ Cancer. 1999;80:219–230.

  37. 37.

    Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.J Exp Med. 1999;190:1669–1678.

  38. 38.

    Matsushita M, Ikeda H, Kizaki M, et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia.Br J Haematol. 2001;112:916–926.

  39. 39.

    Vogt MH, van den Muijsenberg JW, Goulmy E, et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease.Blood. 2002;99:3027–3032.

  40. 40.

    Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens.Nat Med. 2002;8:410–414.

  41. 41.

    Mutis T, Gillespie G, Schrama E, Falkenburg JHF, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatability antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.Nat Med. 1999;5:839–842.

  42. 42.

    Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.Blood. 1999;93: 2336–2341.

  43. 43.

    Maruya E, Saji H, Seki S, et al. Evidence that CD31, CD49b, and CD62L are immunodominant minor histocompatibility antigens in HLA identical sibling bone marrow transplants.Blood. 1998;92: 2169–2176.

  44. 44.

    Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms’ tumor gene (WT1) product.Immunogenetics. 2000;51:99–107.

  45. 45.

    Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.Cancer Res. 2001;61:5964–5968.

  46. 46.

    Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S. Identification of human telomerase reverse transcriptase- derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes.Blood. 2001;97:2903–2907.

  47. 47.

    Schroers R, Huang XF, Hammer J, Zhang J, Chen SY. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.Cancer Res. 2002; 62:2600–2605.

  48. 48.

    Paludan C, Bickham K, Nikiforow S, et al. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt’s lymphoma cells.J Immunol. 2002;169:1593–1603.

  49. 49.

    Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.Blood. 1998;92: 1549–1555.

  50. 50.

    Roskrow MA, Suzuki N, Gan Y, et al. Epstein-Barr virus (EBV)- specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin’s disease.Blood. 1998;91: 2925–2934.

  51. 51.

    Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-longterm results of a clinical trial.Blood. 1997;89:3129–3135.

  52. 52.

    Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.Blood. 2002;99:1517–1526.

  53. 53.

    Clay TM, Custer MC, McKee MD, et al. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.J Immunol. 1999;162:1749–1755.

  54. 54.

    Rivoltini L, Squarcina P, Loftus D, et al. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy.Cancer Res. 1999;59:301–306.

  55. 55.

    Nestle F, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.Nat Med. 1998;4:328–332.

  56. 56.

    Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen.Prostate. 1996;29:371–380.

  57. 57.

    Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone- refractory prostate cancer with antigen-loaded dendritic cells.J Clin Oncol. 2000;18:3894–3903.

  58. 58.

    Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study.Blood. 1999; 93:2411–2419.

  59. 59.

    Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to cd34(+) progenitor-derived dendritic cell vaccine.Cancer Res. 2001;61: 6451–6458.

  60. 60.

    Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.J Clin Invest. 2002; 109:409–417.

  61. 61.

    Wang RF, Wang HY. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells.Nat Biotechnol. 2002;20:149–154.

  62. 62.

    Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded mono-cyte-derived dendritic cells.J Exp Med. 2002;195:1279–1288.

  63. 63.

    Panelli MC, Wunderlich J, Jeffries J, et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.J Immunother. 2000;23:487–498.

  64. 64.

    Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy.J Immunol. 2001;167:7150–7156.

  65. 65.

    Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.Nat Med. 2000;6:332–336.

  66. 66.

    Choudhury BA, Liang JC, Thomas EK, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses.Blood. 1999;93:780–786.

  67. 67.

    Fujii S, Shimizu K, Fujimoto K, et al. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation.Jpn J Cancer Res. 1999;90:1117–1129.

  68. 68.

    Morse MA, Coleman E, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies.Cancer Res. 1999;59:56–58.

  69. 69.

    Rosenberg S, Zhai Y, Yang J, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.J Natl Cancer Inst. 1998;90: 1894–1900.

  70. 70.

    Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.J Natl Cancer Inst. 1995;86:1159–1166.

  71. 71.

    Salgaller M, Marincola F, Cormier J, Rosenberg S. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.Cancer Res. 1996;56: 4749–4757.

  72. 72.

    Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1- human leukocyte antigen-A2 tetramer can be used to isolate low- frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.Cancer Res. 1999;59: 2675–2681.

  73. 73.

    Mutis T, Blokland E, Kester M, Schrama E, Goulmy E. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation.Blood. 2002;100:547–552.

  74. 74.

    Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.Science. 2002;295:2097–2100.

Download references

Author information

Correspondence to Yutaka Kawakami.

About this article

Cite this article

Kawakami, Y. Identification of Human Tumor Antigens Recognized by T-Cells and Their Use for Immunotherapy. Int J Hematol 77, 427–434 (2003). https://doi.org/10.1007/BF02986609

Download citation

Key words

  • Tumor antigens
  • T-cells
  • Dendritic cells
  • Immunotherapy
  • Graft versus leukemia